Evidence map›Paper›PMID 42234263›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovorin.

Yurie Tokito, Kazunaga Ishigaki, Katsuhiko Nara, Go Endo, Hiroto Nishio, Koshiro Fukuda, Tatsunori Suzuki, Yasuyoshi Sato, Naminatsu Takahara, Narikazu Boku and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yurie TokitoDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-Ku, Tokyo, 113-8655, Japan.
Kazunaga IshigakiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-Ku, Tokyo, 113-8655, Japan.
Katsuhiko NaraDepartment of Pharmaceutical Department, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Go EndoDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-Ku, Tokyo, 113-8655, Japan.
Hiroto NishioDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-Ku, Tokyo, 113-8655, Japan.
Koshiro FukudaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-Ku, Tokyo, 113-8655, Japan.
Tatsunori SuzukiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yasuyoshi SatoDepartment of Clinical Oncology, The University of Tokyo Hospital, Tokyo, Japan.
Naminatsu TakaharaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-Ku, Tokyo, 113-8655, Japan. naminatsu.takahara@gmail.com.
Narikazu BokuDepartment of Oncology and General Medicine, Institute of Medical Science, IMSUT Hospital, University of Tokyo, Tokyo, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-Ku, Tokyo, 113-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNano-liposomal irinotecan plus 5-fluorouracil and leucovorin (Nal-IRI/FL) is an established second-line chemotherapy for advanced pancreatic cancer (APC). Standard antiemetic prophylaxis for this moderately emetogenic regimen includes a 5-hydroxytryptamine (5-HT

methodsWe retrospectively compared prophylactic antiemetic efficacy between Dex-omitting (no steroid use) and Dex-sparing (day 1 only) regimens combined with a 5-HT

resultsPatients were categorized into Dex-sparing (n = 61) and Dex-omitting (n = 13) groups. Baseline characteristics were similar except for a higher prevalence of DM in the Dex-omitting group (31% vs. 100%, P < 0.01). TC rates were comparable (80% vs. 69%, P = 0.46). Relative dose intensity was slightly higher in the Dex-omitting group (Nal-IRI, 55% vs. 62%; 5-FU, 59% vs. 68%). Progression-free survival (5.2 vs. 5.0 months, P = 0.84) and overall survival (10.1 vs. 9.4 months, P = 0.56) were also similar.

conclusionsSteroid-omitting antiemetic therapy in combination with a 5-HT

Indexed as

AntiemeticsAntineoplastic Combined Chemotherapy ProtocolsNauseaPancreatic NeoplasmsVomitingAgedDexamethasoneFemaleFluorouracilHumansIrinotecanLeucovorinMaleMiddle AgedRetrospective StudiesSerotonin 5-HT3 Receptor AntagonistsAntiemeticsDexamethasoneFluorouracilIrinotecanLeucovorinSerotonin 5-HT3 Receptor AntagonistsAdvanced pancreatic cancerChemotherapy-induced nausea and vomitingSteroid-omitting antiemetic therapy

Identifiers

PMID42234263
PMCPMC13233883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.